Online inquiry

IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12491MR)

This product GTTS-WQ12491MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MUC5AC gene. The antibody can be applied in Colorectal Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001304359.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4586
UniProt ID P98088
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12491MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13188MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-04950615
GTTS-WQ5127MR IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CAN-04
GTTS-WQ897MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-181
GTTS-WQ8458MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HspE7
GTTS-WQ8537MR IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Hu5A8
GTTS-WQ2625MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 557
GTTS-WQ9813MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JS004
GTTS-WQ12726MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA OMP-305B83
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW